Overall, only 10 samples were MOG-IgG and MOG-IgM double positive: 4/47 (9%) were positive by all 7 live CBAs, all of them with non-MS demyelinating syndromes, and 6/32 (19%) had discordant results, 5 of them with non-MS demyelinating syndromes and 1 with MS. This evidence concerns the gene CD40LG and myeloid sarcoma.